SynthesisBiomarkers in medicine2025
Clinicopathological and prognostic significance of exosomal PD-L1 in cancer therapy.
Synthesis in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PD-L1Biomarker research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe exosomal programmed death ligand-1(exoPD-L1) has recently become a topic of interest in the field of oncology. But the prognostic role of exoPD-L1 in cancer patients is inconsistent across previous studies. Therefore, a quantitative meta-analysis was performed to evaluate the prognostic and clinicopathological value of exoPD-L1 in cancer patients. MATERIALS AND
methodsTwenty eligible studies were included in this study. The relationship between baseline level of exoPD-L1 and clinicopathological features, therapeutic response, overall survival (OS) and progression-free survival (PFS) was evaluated.
resultsPooled analysis indicated that high level of exoPD-L1 was significantly associated with higher tumor stage, positive lymph node metastasis, and advanced TNM stage. Elevated exoPD-L1 was associated with short OS [HR = 1.80 (1.27-2.55),
conclusionexoPD-L1 is an original and effective liquid biomarker for cancer patients. However, large-scale, prospective investigations are still needed to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.